Phase 1 study of 2 high dose intensity schedules of the pan-Notch inhibitor crenigacestat (LY3039478) in combination with prednisone in patients with advanced or metastatic cancer

Analía Azaro, Capucine Baldini, Jordi Rodón, Jean‐Charles Soria, Eunice Yuen, Andrew Lithio, Gerard J. Oakley, Karim A. Benhadji, Christophe Massard